Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers

NCT00258778 is registered in ClinicalTrials.gov with Protalix as lead sponsor.

NCT NCT00258778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers
Lead sponsor
Protalix
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2005
Completion date
January 31, 2006
Enrollment
6
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease